Document is current

Article History

Received: 23 May 2024

Accepted: 29 April 2025

First Online: 9 May 2025

Competing interests

: C. Eng reports grants and personal fees from Roche/Genentech and personal fees from Bayer. T. W. Kim reports grants from AstraZeneca, Pfizer, and Merck Serono outside of the submitted work. J. Bendell reports fees paid to her institution from Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, AbbVie, Array, Onyx, Sanofi, Takeda, Eisai, Celldex, Agios, Sytomx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Ocogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, FORMA, Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Oncology, Unum Therapeutics, Vyriad, Harpoon, ADC, Amgen, Pfizer, Millennium, Imclone, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Seattle Genetics, TempestTx, Shattuck Labs, Synthorx Inc. Revolution Medicines, Bicycle Therapeutics, Zymeworks, Relay Therapeutics, Scholar Rock, NGM Biopharma, Stemcentrx, Beigene, CALGB, Cyteir Therapeutics, Foundation Bio, Innate Pharma, Morphotex, Ongologie, NuMab, AtalasMedx, Treadwell Therapeutics, IGM Biosciences, Mabspace, Hutchinson MediPharma, REPAIR Therapeutics, NeoImmune Tech; J. Bendell also reports consulting/advisory role to her institution from Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, Medimmune, Celgene, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, ARMO, Ipsen, Merrimack, Oncogenex, FORMA, Arch Oncology, Prelude Therapeutics, Phoenix Bio, Cyteir, Molecular Partners, Innate, Torque, Tizona, Janssen, Tolero, TD2(Translational Drug Development), Amgen, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Agios, Bicycle Therapeutics, Relay Therapeutics, Evelo, Pfizer, Piper Biotech, Samsung Bioepios, Fusion Therapeutics; J. Bendell also reports food /beverage and travel from Gilead, Genentech/Roche, BMS, Lilly, Merck, MedImmune, Celgene, Taiho, Novatis, OncoMed, BI, ARMO, Ipsen, Oncogenex, FORMA. F. Ciardiello reports personal fees from Roche/Genentech, Merck Serono, Pfizer, Amgen, Servier, Lilly, Bayer, Bristol-Myers Squibb, and Celgene; and grants from Bayer, Amgen, and Merck Serono. H Hamidi, Y. Shi, E. Lin, M. Wongchenko, and Y. Yan are employees and stockholders of Roche/Genentech. C. Bais, X. Qu, R. M. Johnson, F. de Sousa e Melo, A. Mancini, and D. Shames are former employees of Genentech. E. S. Sokol, S. Sivakuma, and B. Kaplan are employees at Foundation Medicine, Inc., a wholly owned subsidiary of Roche Holdings, Inc., and Roche Finance Ltd, and have an equity interest in Roche.